Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up – Here’s What Happened

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) gapped up prior to trading on Wednesday . The stock had previously closed at $17.61, but opened at $19.76. Sarepta Therapeutics shares last traded at $22.2830, with a volume of 6,241,387 shares trading hands.

More Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Company published encouraging early Phase 1/2 data for SRP‑1001 (FSHD1) and SRP‑1003 (DM1): dose‑dependent muscle exposure, early biomarker effects and favorable tolerability — potential to open new rare‑disease franchises and justify re‑rating. Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
• Positive Sentiment: Market reaction: outlets reported a ~20% intraday gain after the data release, reflecting short‑term buying and renewed investor interest in Sarepta’s diversified pipeline beyond its traditional exon‑skipping and micro‑dystrophin assets. Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?
• Neutral Sentiment: The company hosted/announced a webcast to present the data (investors should review the webcast/transcript for read‑throughs on biomarker durability, safety and next trial steps). Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
• Neutral Sentiment: Short‑interest reporting in the feed showed anomalous “0 shares” entries for March (data appears unreliable); not a clear signal of crowd positioning.
• Negative Sentiment: Fundamentals and valuation risks remain: Sarepta recently reported a large EPS miss, negative margins and revenue declines year‑over‑year — any enthusiasm will be weighed against execution risk, commercialization performance of existing products, and cash/runway considerations.
• Negative Sentiment: Analyst/market skepticism about valuation persists — commentary has framed the company as under‑priced relative to its business potential, which can limit the upside if upcoming data or commercial metrics don’t show clear progression. Sarepta Therapeutics: A $2B Business Priced Like It’s Broken

Analyst Ratings Changes

SRPT has been the topic of several analyst reports. Citigroup lifted their target price on shares of Sarepta Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a research note on Tuesday, March 10th. Royal Bank Of Canada increased their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a research report on Thursday, January 8th. Jefferies Financial Group reissued a “buy” rating and issued a $30.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. Barclays began coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 28th. They issued an “equal weight” rating and a $20.00 price objective on the stock. Finally, Loop Capital set a $25.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. Nine investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $32.15.

Sarepta Therapeutics Trading Up 28.4%

The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32. The firm has a market capitalization of $2.37 billion, a PE ratio of -2.68, a P/E/G ratio of 0.28 and a beta of 0.42. The stock’s 50-day simple moving average is $18.68 and its 200-day simple moving average is $19.94.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The company had revenue of $442.93 million during the quarter, compared to analysts’ expectations of $390.95 million. Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The company’s revenue for the quarter was down 32.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.90 earnings per share. As a group, sell-side analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $17.02, for a total value of $123,207.78. Following the completion of the sale, the director directly owned 1,765 shares in the company, valued at $30,040.30. This trade represents a 80.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 7.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC bought a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $25,000. iSAM Funds UK Ltd bought a new position in Sarepta Therapeutics in the third quarter worth $25,000. Ancora Advisors LLC lifted its position in Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,000 shares during the period. Byrne Asset Management LLC purchased a new position in Sarepta Therapeutics during the third quarter valued at $33,000. Finally, Allworth Financial LP boosted its holdings in shares of Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 1,721 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.